JLL secured a $406 million fixed-rate loan through Wells Fargo and Morgan Stanley for Regent Properties' Trammell Crow Center, a 50-story office tower in Dallas' Arts District. The building is 92% leased and recently underwent a $182 million renovation, adding retail space, a new parking structure, and upgraded amenities. This financing highlights strong institutional interest in high-quality office assets in growth markets like Dallas. The loan supports continued value creation in a prime location with cultural and retail connectivity.
The JLL-arranged $406 million financing for the Trammell Crow Center in Dallas is presented here with Pluang's Real Estate sector data for context. For readers following this sector, as of Sep 24, 2026 23:32 WIB, 10 of 26 priced US Real Estate stocks on Pluang rose while 16 fell. Among them, Digital Realty Trust (DLR) rose 0.69% to USD 182.71 with a typical hold time of 92 days, CubeSmart (CUBE) fell 0.63% to USD 37.90 with a 100-day hold, and Equinix (EQIX) increased 0.53% to USD 1,043.13 with 100% buy order activity and a 109-day typical hold time.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
